Helius Med Technolog (HSDT) 2.5380 $HSDT
Helius Medical Technologies Announces OTCQB Listing
Business Wire - Tue Feb 10, 11:44AM CST
Helius Medical Technologies, Inc. (CSE:HSM) (OTCQB:HSDT) ("Helius" or the "Company"
is pleased to announce that its common shares have commenced trading on the OTCQB marketplace in the US, under the symbol HSDT.
U.S. Army, Helius Medical Technologies Modify CRADA To Speed PoNS(TM) Device Development
Business Wire - Mon Jan 19, 9:15AM CST
Helius Medical Technologies ("Helius", or the "Company" [through its wholly owned division NeuroHabilitation Corporation ("NHC" ], and the U.S. Army Medical Research and Material Command ("USAMRMC" have modified an existing Cooperative Research and Development Agreement ("CRADA" to speed up the development of the company's Portable Neuromodulation Stimulator ("PoNS(TM)" device, a non-invasive brain stimulation device that is being developed for the treatment of balance disorder in patients with mild-to-moderate Traumatic Brain Injury ("mTBI" . The PoNS(TM) is an investigational medical device that is designed to induce neuromodulation by stimulating the cranial nerves found in the tongue.
Helius Medical Technologies Inventors' Granted US Patent No. 8,909,345, "Non-Invasive Neuromodulation (NINM) for Rehabilitation of Brain Function"
Business Wire - Tue Dec 16, 9:15AM CST
Helius Medical Technologies, Inc. (CSE:HSM) ("Helius", or the "Company" announced today that the US Patent and Trademark Office (USPTO) issued a second broad patent related to the Portable Neuromodulation Stimulator (PoNS(TM)) device and the associated therapeutic modality. The PoNS, an investigational medical device that induces neuromodulation by stimulating the cranial nerves found in the tongue, is initially being studied for the treatment of balance disorder symptoms caused by Traumatic Brain Injury ("TBI" and MS.
Helius Medical Technologies Grants Stock Options and Adds to Scientific and Medical Advisory Board
Business Wire - Mon Dec 08, 7:48PM CST
Helius Medical Technologies (CSE:HSM) ("HMT", "Helius" or the "Company" , a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, announces that it has granted incentive stock options, exercisable to purchase up to an aggregate of 950,000 shares of the Company, to directors, officers, and consultants of the Company.
Helius Medical Technologies Names Dr. Jonathan Sackier, MB ChB, FRCS, FACS, as Chief Medical Officer
TheNewswire.ca - Tue Dec 02, 10:35AM CST
(via Thenewswire.ca)
Helius Medical Technologies Names The Trout Group LLC to Support Investor Relations in the US
Business Wire - Tue Nov 25, 9:15AM CST
Helius Medical Technologies (CSE: HSM) ("HMT", "Helius" or the "Company" a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, has appointed The Trout Group LLC, a leading international New York headquartered life sciences investor relations and strategic advisory firm. The Trout Group will work with Helius to increase the Company's exposure to the capital markets by developing relationships with portfolio managers, investment bankers, and industry analysts in the United States and Europe.
Helius Medical Technologies Retains The Trout Group LLC to Support Investor Relations in The US
ACCESSWIRE - Tue Nov 25, 8:26AM CST
Newtown, PA / ACCESSWIRE / November 25, 2014 / Helius Medical Technologies (CSE: HSM) ("HMT", "Helius" or the "Company" , a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, has retained The Trout Group LLC, a leading international New York-headquartered life sciences investor relations and strategic advisory firm. The Trout Group will work with Helius to increase the Company's exposure to the capital markets by developing relationships with portfolio managers, investment bankers, and industry analysts in the United States and Europe.
Helius Medical Technologies Announces Russian Distribution Agreement for PoNS(TM) Device
Business Wire - Fri Nov 21, 9:15AM CST
Helius Medical Technologies (CSE:HSM) ("HMT," "Helius" or the "Company" a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, has signed a distribution agreement with Altair LLC, a Russian medical distribution company. Helius is working on the development of the PoNS(TM), an investigational medical device that induces neuromodulation by stimulating the cranial nerves found in the tongue. It is initially being studied for the treatment of balance disorder symptoms caused by Traumatic Brain Injury ("TBI" and Multiple Sclerosis. Neurologist Evgeny Bugorskiy, owner of Altair LLC, has been working alongside PoNS(TM) inventor, Yuri Danilov, for the past ten years and has been evaluating the device for the treatment of a number of neurological indications including cerebral palsy, stroke and TBI.
Helius Medical Technologies Announces OTCQB Listing
Business Wire - Tue Feb 10, 11:44AM CST
Helius Medical Technologies, Inc. (CSE:HSM) (OTCQB:HSDT) ("Helius" or the "Company"
is pleased to announce that its common shares have commenced trading on the OTCQB marketplace in the US, under the symbol HSDT. U.S. Army, Helius Medical Technologies Modify CRADA To Speed PoNS(TM) Device Development
Business Wire - Mon Jan 19, 9:15AM CST
Helius Medical Technologies ("Helius", or the "Company"
[through its wholly owned division NeuroHabilitation Corporation ("NHC" ], and the U.S. Army Medical Research and Material Command ("USAMRMC" have modified an existing Cooperative Research and Development Agreement ("CRADA" to speed up the development of the company's Portable Neuromodulation Stimulator ("PoNS(TM)" device, a non-invasive brain stimulation device that is being developed for the treatment of balance disorder in patients with mild-to-moderate Traumatic Brain Injury ("mTBI" . The PoNS(TM) is an investigational medical device that is designed to induce neuromodulation by stimulating the cranial nerves found in the tongue. Helius Medical Technologies Inventors' Granted US Patent No. 8,909,345, "Non-Invasive Neuromodulation (NINM) for Rehabilitation of Brain Function"
Business Wire - Tue Dec 16, 9:15AM CST
Helius Medical Technologies, Inc. (CSE:HSM) ("Helius", or the "Company"
announced today that the US Patent and Trademark Office (USPTO) issued a second broad patent related to the Portable Neuromodulation Stimulator (PoNS(TM)) device and the associated therapeutic modality. The PoNS, an investigational medical device that induces neuromodulation by stimulating the cranial nerves found in the tongue, is initially being studied for the treatment of balance disorder symptoms caused by Traumatic Brain Injury ("TBI" and MS. Helius Medical Technologies Grants Stock Options and Adds to Scientific and Medical Advisory Board
Business Wire - Mon Dec 08, 7:48PM CST
Helius Medical Technologies (CSE:HSM) ("HMT", "Helius" or the "Company"
, a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, announces that it has granted incentive stock options, exercisable to purchase up to an aggregate of 950,000 shares of the Company, to directors, officers, and consultants of the Company. Helius Medical Technologies Names Dr. Jonathan Sackier, MB ChB, FRCS, FACS, as Chief Medical Officer
TheNewswire.ca - Tue Dec 02, 10:35AM CST
(via Thenewswire.ca)
Helius Medical Technologies Names The Trout Group LLC to Support Investor Relations in the US
Business Wire - Tue Nov 25, 9:15AM CST
Helius Medical Technologies (CSE: HSM) ("HMT", "Helius" or the "Company"
a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, has appointed The Trout Group LLC, a leading international New York headquartered life sciences investor relations and strategic advisory firm. The Trout Group will work with Helius to increase the Company's exposure to the capital markets by developing relationships with portfolio managers, investment bankers, and industry analysts in the United States and Europe. Helius Medical Technologies Retains The Trout Group LLC to Support Investor Relations in The US
ACCESSWIRE - Tue Nov 25, 8:26AM CST
Newtown, PA / ACCESSWIRE / November 25, 2014 / Helius Medical Technologies (CSE: HSM) ("HMT", "Helius" or the "Company"
, a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, has retained The Trout Group LLC, a leading international New York-headquartered life sciences investor relations and strategic advisory firm. The Trout Group will work with Helius to increase the Company's exposure to the capital markets by developing relationships with portfolio managers, investment bankers, and industry analysts in the United States and Europe. Helius Medical Technologies Announces Russian Distribution Agreement for PoNS(TM) Device
Business Wire - Fri Nov 21, 9:15AM CST
Helius Medical Technologies (CSE:HSM) ("HMT," "Helius" or the "Company"
a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, has signed a distribution agreement with Altair LLC, a Russian medical distribution company. Helius is working on the development of the PoNS(TM), an investigational medical device that induces neuromodulation by stimulating the cranial nerves found in the tongue. It is initially being studied for the treatment of balance disorder symptoms caused by Traumatic Brain Injury ("TBI" and Multiple Sclerosis. Neurologist Evgeny Bugorskiy, owner of Altair LLC, has been working alongside PoNS(TM) inventor, Yuri Danilov, for the past ten years and has been evaluating the device for the treatment of a number of neurological indications including cerebral palsy, stroke and TBI. 
